ArticleInternational journal of urology : official journal of the Japanese Urological Association2025
Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.
Article in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe association between the response to first-line chemotherapy and maintenance of avelumab remains unclear. We identified factors associated with the response to avelumab in patients with advanced urothelial carcinoma using real-world data.
methodsWe retrospectively enrolled 100 patients with advanced urothelial carcinoma treated with maintenance avelumab therapy between March 2021 and April 2024 at Nagoya University and nine affiliated hospitals. The complete/partial-response group was defined as patients with complete response or partial response as the best response to first-line chemotherapy. The stable disease group was defined as patients with stable disease as the best response to first-line chemotherapy.
resultsSeven patients (7.0%) achieved complete response, 65 (65.0%) achieved partial response, and 28 (28.0%) achieved stable disease as the best response to first-line chemotherapy. Regarding avelumab therapy, the complete/partial-response group had significantly better progression-free survival than the stable disease group (median: 11.1 vs. 3.2 months, p < 0.001). In multivariate analyses, the best response to first-line chemotherapy was the only independent risk factor for progression-free survival (hazard ratio = 1.844, 95% confidence interval = 1.002-3.394; p = 0.049). Overall survival was significantly shorter in the stable disease group than in the complete/partial-response group (median: 14.1 months vs. not reached, p < 0.001). Multivariate analyses revealed significant associations between poor overall survival and performance status (hazard ratio = 2.175, 95% confidence interval = 1.030-4.592; p = 0.042) and the best response to first-line chemotherapy (hazard ratio = 4.174, 95% confidence interval = 1.975-8.824; p < 0.001).
conclusionsThe best response to first-line chemotherapy may predict the clinical outcome of patients with advanced urothelial carcinoma treated with avelumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.